Literature DB >> 7035934

Mutagenicity of a series of hexacoordinate chromium (III) compounds.

G Warren, P Schultz, D Bancroft, K Bennett, E H Abbott, S Rogers.   

Abstract

17 chromium(III) compounds have been tested for DNA-damaging capabilities using an E. coli differential repair assay and for mutagenicity in strains of Salmonella typhimurium. 4 of these compounds were active in both assays. Another 4 compounds were positive only in the repair assay and 9 were devoid of activity in both assays. Most of the doubly active complexes contain aromatic amine ligands like 2,2'-bipyridine and 1,10-phenanthroline. Closely related complexes of ligands derived from saturated amines are much less active. It appears that chromium(III) in the proper ligand environment can have considerable genetic toxicity and could represent one of the several possible ultimate species in a mechanism for chromium mutagenesis and carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7035934     DOI: 10.1016/0165-1218(81)90073-2

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

1.  Carcinogenicity of chromium and its salts.

Authors: 
Journal:  Br J Ind Med       Date:  1987-05

2.  Mutagenic activity of copper(II) chromate and dichromate complexes with polypyridines.

Authors:  K Szyba; M C Golonka; K Gasiorowski; J Urban
Journal:  Biometals       Date:  1992       Impact factor: 2.949

3.  In vitro studies on the DNA impairments induced by Cr(III) complexes with cellular reductants.

Authors:  B Gulanowski; M Cieślak-Golonka; K Szyba; J Urban
Journal:  Biometals       Date:  1994-04       Impact factor: 2.949

Review 4.  Metabolism and possible health effects of aluminum.

Authors:  P O Ganrot
Journal:  Environ Health Perspect       Date:  1986-03       Impact factor: 9.031

Review 5.  A possible role for chromium(III) in genotoxicity.

Authors:  E T Snow
Journal:  Environ Health Perspect       Date:  1991-05       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.